GlaxoSmithKline (GS71) AI Stock Analysis

0 Followers

GlaxoSmithKline

(BX Swiss:GS71)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Specialty Medicines GrowthBroad-based specialty-medicine growth across HIV, respiratory and oncology reduces reliance on a single product and supports a stronger long-term mix. Double-digit performance from several launches also indicates meaningful commercial traction for GSK’s differentiated portfolio.

Negative Factors

Leverage and Interest BurdenGSK’s meaningful debt load reduces financial flexibility and makes earnings more sensitive to refinancing costs. Higher interest expense, including financing related to Nuvalent, can absorb cash that could otherwise support research, acquisitions or debt reduction.

GlaxoSmithKline (GS71) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 73.23B
Dividend Yield: 3.66%
Average Volume (3M): ―
Price to Earnings (P/E): 16.9
Beta (1Y): ―
Revenue Growth: 0.46%
EPS Growth: -22.43%
Country: Switzerland
Employees: 66,841
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

GlaxoSmithKline Business Overview & Revenue Model

Company Description

GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United State...

GlaxoSmithKline Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 02, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. GSK reported solid Q3 sales, operating profit, specialty-medicine growth, cash generation, launch progress, and a significant acceleration in phase III development. The company also reaffirmed 2026 guidance and highlighted encouraging clinical and commercial momentum across oncology, respiratory, HIV, hepatitis B, vaccines, and business development. The main negatives were higher restructuring charges, sharply increased R&D and interest costs, foreign-exchange headwinds, vaccine and inhaler-market pressure, Shingrix inventory and China destocking, and unresolved analysis around the four-monthly APRETUDE formulation. These challenges were meaningful but were outweighed by the breadth of the reported operational and pipeline progress.

Positive Updates

Strong Q3 Revenue and Operating Momentum

Q3 sales increased 5% to GBP 8.9 billion, core operating profit grew 5%, and core earnings per share increased 1%. Specialty medicines were the primary growth driver, including respiratory and oncology launches.

Negative Updates

EPS Growth Lagged Operating Profit Growth

Core EPS increased only 1% despite 5% growth in core operating profit. The differential was attributed to higher interest costs following the Nuvalent acquisition and a higher tax rate in the quarter.

Company Guidance

GSK reconfirmed 2026 guidance: sales are expected in the upper half of the range, core operating profit is also expected in the upper half of the range, margin remains on track to be more than 31% at constant rates, SG&A is projected to be broadly stable, royalties are now upgraded to around GBP 900 million for the year, R&D is expected to grow significantly ahead of sales for the year, with 22 phase III starts versus 10 expected at the start of the year, EPS growth is expected to be in the low half of the range, full year interest is expected to be GBP 700 million-GBP 750 million, including around GBP 160 million relating to the acquisition of Nuvalent, and foreign exchange headwinds are expected to be -1% on sales and -3% on operating profit; the company remains on track to deliver around GBP 10 billion CGFO at constant rates and now expects charges of up to GBP 1 billion in 2026.

GlaxoSmithKline Risk Analysis

GlaxoSmithKline disclosed 1 risk factors in its most recent earnings report. GlaxoSmithKline reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.Text to select risk factors from:Q4, 2024

GlaxoSmithKline Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:GS71 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:AZN	80Outperform	GBP 214.96B	26.01	22.31%	1.74%	4.55%	14.19%
GB:HIK	74Outperform	GBP 3.62B	13.11	15.05%	3.64%	2.48%	3.36%
GB:SN	72Outperform	GBP 9.25B	19.79	12.25%	2.63%	2.17%	27.33%
GB:HLN	63Neutral	GBP 28.41B	17.95	9.89%	1.41%	1.21%	8.33%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

CH:GS71 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:GS71	GlaxoSmithKline plc (UK)	26.11	0.00	0.00%
GB:AZN	AstraZeneca plc	13760.00	1519.16	12.41%
GB:HIK	Hikma Pharmaceuticals	1743.00	50.92	3.01%
GB:SN	Smith & Nephew (UK)	1117.50	-239.45	-17.65%
GB:BXP	Beximco Pharmaceuticals Limited Sponsored GDR RegS	54.00	12.92	31.44%
GB:HLN	Haleon PLC	325.60	-24.50	-7.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

GlaxoSmithKline AI Stock Analysis